Symbols / AMRX
AMRX Chart
About
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 4.26B |
| Enterprise Value | 6.65B | Income | 72.06M | Sales | 3.02B |
| Book/sh | -0.23 | Cash/sh | 0.91 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8700 | IPO | — |
| P/E | 61.50 | Forward P/E | 11.58 | PEG | — |
| P/S | 1.41 | P/B | -60.13 | P/C | — |
| EV/EBITDA | 10.32 | EV/Sales | 2.20 | Quick Ratio | 1.39 |
| Current Ratio | 2.17 | Debt/Eq | 45095.52 | LT Debt/Eq | — |
| EPS (ttm) | 0.22 | EPS next Y | 1.17 | EPS Growth | — |
| Revenue Growth | 11.50% | Earnings | 2026-05-01 | ROA | 7.32% |
| ROE | — | ROIC | — | Gross Margin | 37.38% |
| Oper. Margin | 14.06% | Profit Margin | 2.39% | Shs Outstand | 314.63M |
| Shs Float | 176.95M | Short Float | 5.23% | Short Ratio | 2.95 |
| Short Interest | — | 52W High | 15.42 | 52W Low | 6.68 |
| Beta | 1.30 | Avg Volume | 2.53M | Volume | 770.85K |
| Target Price | $16.80 | Recom | Buy | Prev Close | $13.25 |
| Price | $13.53 | Change | 2.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.80
Mean price target
2. Current target
$13.53
Latest analyst target
3. DCF / Fair value
$11.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.53
Low
$15.00
High
$18.00
Mean
$16.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | Truist Securities | Buy → Buy | $17 |
| 2025-12-09 | init | Barclays | — → Overweight | $15 |
| 2025-10-31 | reit | Piper Sandler | Overweight → Overweight | $13 |
| 2025-09-16 | main | JP Morgan | Overweight → Overweight | $14 |
| 2025-03-03 | main | Barclays | Overweight → Overweight | $11 |
| 2025-02-24 | up | JP Morgan | Neutral → Overweight | $12 |
| 2024-11-11 | main | Piper Sandler | Overweight → Overweight | $11 |
| 2024-10-02 | main | Truist Securities | Buy → Buy | $12 |
| 2024-09-06 | up | JP Morgan | Underweight → Neutral | $9 |
| 2024-08-13 | main | Barclays | Overweight → Overweight | $10 |
| 2024-08-12 | main | Truist Securities | Buy → Buy | $10 |
| 2024-05-06 | main | Goldman Sachs | Buy → Buy | $8 |
| 2024-05-06 | reit | Truist Securities | Buy → Buy | $9 |
| 2024-03-21 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2024-03-04 | main | Goldman Sachs | Buy → Buy | $6 |
| 2024-01-29 | main | Barclays | Overweight → Overweight | $8 |
| 2023-11-08 | main | Truist Securities | Buy → Buy | $7 |
| 2023-09-06 | reit | Truist Securities | Buy → Buy | $6 |
| 2023-08-07 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2023-08-07 | main | Truist Securities | Buy → Buy | $6 |
- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat ue, 10 Mar 2026 10
- Reassessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Long Term Returns And A High Current P/E Ratio - simplywall.st ue, 10 Mar 2026 00
- Amneal co-chief to speak at Miami Barclays healthcare investor event - Stock Titan hu, 05 Mar 2026 21
- Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo Finance Mon, 23 Feb 2026 08
- How AMRX stock responds to policy changes - 2025 Technical Patterns & Expert Approved Trade Ideas - Naître et grandir Sat, 07 Mar 2026 04
- Why Amneal (AMRX) Stock Is Trading Lower Today - Finviz Fri, 27 Feb 2026 08
- Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat Sat, 07 Mar 2026 08
- New Strong Buy Stocks for March 9th - Yahoo Finance Mon, 09 Mar 2026 12
- Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations - Finviz Fri, 27 Feb 2026 08
- A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance Sun, 01 Mar 2026 21
- Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat ue, 03 Mar 2026 13
- The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release - simplywall.st Fri, 27 Feb 2026 08
- Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates - Yahoo Finance Fri, 27 Feb 2026 08
- Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance Fri, 27 Feb 2026 14
- Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance Fri, 30 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 548953 | — | — | BOYER ANDREW S | Officer | — | 2026-03-04 00:00:00 | D | nan |
| 1 | 886468 | — | — | PATEL CHIRAG K | Chief Executive Officer | — | 2026-03-04 00:00:00 | D | nan |
| 2 | 508499 | — | — | SHAH NIKITA | Officer | — | 2026-03-04 00:00:00 | D | nan |
| 3 | 886468 | — | — | PATEL CHINTU | Chief Executive Officer | — | 2026-03-04 00:00:00 | D | nan |
| 4 | 426819 | — | — | DALY JASON B. | Officer | — | 2026-03-04 00:00:00 | D | nan |
| 5 | 633865 | — | — | KONIDARIS TASOS | Chief Financial Officer | — | 2026-03-04 00:00:00 | D | nan |
| 6 | 50000 | — | Sale at price 11.72 per share. | NARK THEODORE C. | Director | — | 2025-11-17 00:00:00 | D | 586000.0 |
| 7 | 131856 | — | Conversion of Exercise of derivative security at price 2.75 per share. | SHAH NIKITA | Officer | — | 2025-11-12 00:00:00 | D | 362604.0 |
| 8 | 131856 | — | Sale at price 11.92 per share. | SHAH NIKITA | Officer | — | 2025-11-12 00:00:00 | D | 1571724.0 |
| 9 | 32000 | — | Sale at price 9.23 per share. | KIELY JOHN J. | Director | — | 2025-08-27 00:00:00 | D | 295360.0 |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -224.45K | -32.88M | -7.52M | -62.34M |
| TaxRateForCalcs | 0.08 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | 606.64M | 596.35M | 435.58M | 447.27M |
| TotalUnusualItems | -2.77M | -156.57M | -35.83M | -296.85M |
| TotalUnusualItemsExcludingGoodwill | -2.77M | -156.57M | -35.83M | -296.85M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 72.06M | -116.89M | -83.99M | -129.99M |
| ReconciledDepreciation | 223.57M | 236.19M | 229.40M | 240.18M |
| ReconciledCostOfRevenue | 1.91B | 1.77B | 1.57B | 1.43B |
| EBITDA | 603.87M | 439.77M | 399.76M | 150.43M |
| EBIT | 380.30M | 203.58M | 170.36M | -89.75M |
| NetInterestIncome | -272.46M | -258.60M | -251.43M | -158.67M |
| InterestExpense | 241.09M | 258.60M | 210.63M | 158.38M |
| NormalizedIncome | 74.60M | 6.81M | -55.69M | 104.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 72.06M | -116.89M | -83.99M | -129.99M |
| TotalExpenses | 2.62B | 2.45B | 2.15B | 2.02B |
| TotalOperatingIncomeAsReported | 394.10M | 249.33M | 204.37M | -94.93M |
| DilutedAverageShares | 308.98M | 176.14M | 150.94M | 151.82M |
| BasicAverageShares | 308.98M | 176.14M | 150.94M | 148.92M |
| DilutedEPS | -0.38 | -0.48 | -0.86 | 0.07 |
| BasicEPS | -0.38 | -0.48 | -0.86 | 0.07 |
| DilutedNIAvailtoComStockholders | 72.06M | -116.89M | -83.99M | -129.99M |
| NetIncomeCommonStockholders | 72.06M | -116.89M | -83.99M | -129.99M |
| NetIncome | 72.06M | -116.89M | -83.99M | -129.99M |
| MinorityInterests | -55.88M | -43.01M | -35.27M | 124.80M |
| NetIncomeIncludingNoncontrollingInterests | 127.93M | -73.88M | -48.72M | -254.79M |
| NetIncomeContinuousOperations | 127.93M | -73.88M | -48.72M | -254.79M |
| TaxProvision | 11.28M | 18.86M | 8.45M | 6.66M |
| PretaxIncome | 139.21M | -55.01M | -40.27M | -248.13M |
| OtherIncomeExpense | 13.75M | -144.79M | -27.58M | -278.38M |
| OtherNonOperatingIncomeExpenses | 16.52M | 11.78M | 8.24M | 18.46M |
| SpecialIncomeCharges | -10.41M | -149.73M | -37.50M | -284.48M |
| GainOnSaleOfBusiness | 0.00 | 0.00 | ||
| OtherSpecialCharges | 6.20M | 147.37M | 35.75M | 281.62M |
| RestructuringAndMergernAcquisition | 4.21M | 2.35M | 1.75M | 2.86M |
| GainOnSaleOfSecurity | 7.63M | -6.85M | 1.67M | -12.36M |
| NetNonOperatingInterestIncomeExpense | -272.46M | -258.60M | -251.43M | -158.67M |
| TotalOtherFinanceCost | 31.36M | 40.80M | 291.00K | |
| InterestExpenseNonOperating | 241.09M | 258.60M | 210.63M | 158.38M |
| OperatingIncome | 397.91M | 348.37M | 238.75M | 188.92M |
| OperatingExpense | 715.39M | 672.07M | 581.82M | 595.79M |
| OtherOperatingExpenses | -5.24M | -930.00K | -15.63M | -3.96M |
| OtherTaxes | 50.68M | 3.12M | 631.00K | |
| ResearchAndDevelopment | 193.81M | 196.56M | 167.78M | 200.05M |
| SellingGeneralAndAdministration | 526.83M | 476.44M | 429.68M | 399.70M |
| GrossProfit | 1.11B | 1.02B | 820.57M | 784.71M |
| CostOfRevenue | 1.91B | 1.77B | 1.57B | 1.43B |
| TotalRevenue | 3.02B | 2.79B | 2.39B | 2.21B |
| OperatingRevenue | 3.02B | 2.79B | 2.39B | 2.21B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 314.56M | 309.88M | 306.56M | 151.49M |
| ShareIssued | 314.56M | 309.88M | 306.56M | 151.49M |
| NetDebt | 2.29B | 2.38B | 2.55B | 2.70B |
| TotalDebt | 2.69B | 2.59B | 2.75B | 2.85B |
| TangibleBookValue | -1.23B | -1.44B | -1.47B | -1.40B |
| InvestedCapital | 2.50B | 2.38B | 2.66B | 3.02B |
| WorkingCapital | 1.03B | 458.04M | 531.27M | 659.02M |
| NetTangibleAssets | -1.23B | -1.44B | -1.47B | -1.40B |
| CapitalLeaseObligations | 117.17M | 107.14M | 109.95M | 123.49M |
| CommonStockEquity | -70.79M | -109.27M | 19.78M | 298.42M |
| TotalCapitalization | 2.49B | 2.05B | 2.45B | 2.93B |
| TotalEquityGrossMinorityInterest | -71.33M | -109.51M | 20.01M | 183.98M |
| MinorityInterest | -535.00K | -245.00K | 230.00K | -114.44M |
| StockholdersEquity | -70.79M | -109.27M | 19.78M | 298.42M |
| GainsLossesNotAffectingRetainedEarnings | -110.73M | -65.51M | -32.35M | 9.94M |
| OtherEquityAdjustments | -110.73M | -65.51M | -32.35M | 9.94M |
| RetainedEarnings | -535.00M | -607.06M | -490.18M | -406.18M |
| AdditionalPaidInCapital | 571.79M | 560.21M | 539.24M | 691.63M |
| CapitalStock | 3.15M | 3.10M | 3.07M | 3.04M |
| CommonStock | 3.15M | 3.10M | 3.07M | 3.04M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.75B | 3.61B | 3.45B | 3.62B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.87B | 2.48B | 2.61B | 2.86B |
| OtherNonCurrentLiabilities | 92.73M | 94.05M | 8.21M | 70.17M |
| PreferredSecuritiesOutsideStockEquity | 77.29M | 64.97M | 41.29M | 24.95M |
| DerivativeProductLiabilities | 0.00 | 11.47M | ||
| EmployeeBenefits | 11.35M | 17.12M | 21.28M | 16.74M |
| DuetoRelatedPartiesNonCurrent | 19.13M | 50.90M | 11.78M | 9.65M |
| TradeandOtherPayablesNonCurrent | 0.00 | 1.25M | 497.00K | 563.00K |
| LongTermDebtAndCapitalLeaseObligation | 2.67B | 2.25B | 2.52B | 2.74B |
| LongTermCapitalLeaseObligation | 102.36M | 91.09M | 95.45M | 108.81M |
| LongTermDebt | 2.57B | 2.16B | 2.43B | 2.63B |
| CurrentLiabilities | 881.63M | 1.13B | 846.60M | 752.80M |
| OtherCurrentLiabilities | 43.26M | 31.75M | 76.99M | 107.48M |
| CurrentDebtAndCapitalLeaseObligation | 21.58M | 340.25M | 227.62M | 104.64M |
| CurrentCapitalLeaseObligation | 14.81M | 16.04M | 14.50M | 14.68M |
| CurrentDebt | 6.76M | 324.21M | 213.12M | 89.96M |
| OtherCurrentBorrowings | 6.76M | 224.21M | 34.12M | 29.96M |
| LineOfCredit | 0.00 | 100.00M | 179.00M | 60.00M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 79.89M | 72.96M | 71.12M | 54.04M |
| PayablesAndAccruedExpenses | 736.91M | 684.80M | 470.86M | 486.64M |
| CurrentAccruedExpenses | 426.76M | 403.80M | 309.74M | 307.95M |
| InterestPayable | 18.66M | 1.58M | ||
| Payables | 310.16M | 281.00M | 161.12M | 178.69M |
| OtherPayable | 10.23M | 10.23M | 10.23M | 10.23M |
| DuetoRelatedPartiesCurrent | 55.48M | 22.31M | 7.32M | 2.48M |
| TotalTaxPayable | 359.00K | 2.52M | ||
| AccountsPayable | 254.67M | 258.69M | 143.57M | 165.98M |
| TotalAssets | 3.68B | 3.50B | 3.47B | 3.80B |
| TotalNonCurrentAssets | 1.77B | 1.91B | 2.09B | 2.39B |
| OtherNonCurrentAssets | 9.30M | 5.28M | 7.13M | 8.19M |
| NonCurrentPrepaidAssets | 37.55M | 16.11M | 6.88M | 7.23M |
| NonCurrentDeferredAssets | 5.20M | 2.82M | 4.43M | 2.21M |
| FinancialAssets | 5.76M | 35.92M | 37.09M | 85.59M |
| GoodwillAndOtherIntangibleAssets | 1.16B | 1.33B | 1.49B | 1.69B |
| OtherIntangibleAssets | 563.50M | 732.38M | 890.42M | 1.10B |
| Goodwill | 595.47M | 597.44M | 598.63M | 598.85M |
| NetPPE | 550.33M | 523.69M | 550.14M | 589.36M |
| AccumulatedDepreciation | -606.17M | -563.52M | -508.03M | -445.97M |
| GrossPPE | 1.16B | 1.09B | 1.06B | 1.04B |
| Leases | 133.83M | 130.91M | 126.46M | 124.67M |
| ConstructionInProgress | 92.91M | 78.20M | 67.67M | 69.34M |
| OtherProperties | 107.38M | 98.78M | 102.56M | 119.55M |
| MachineryFurnitureEquipment | 568.09M | 546.56M | 524.61M | 485.44M |
| BuildingsAndImprovements | 234.60M | 224.66M | 227.84M | 225.63M |
| LandAndImprovements | 19.69M | 8.11M | 9.02M | 10.71M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.91B | 1.59B | 1.38B | 1.41B |
| RestrictedCash | 28.84M | 7.87M | 7.57M | 9.25M |
| PrepaidAssets | 54.13M | 48.37M | 51.71M | 48.95M |
| Inventory | 606.30M | 612.45M | 581.38M | 530.74M |
| FinishedGoods | 323.49M | 351.92M | 304.08M | 247.61M |
| WorkInProcess | 55.45M | 52.84M | 59.56M | 58.52M |
| RawMaterials | 227.35M | 207.70M | 217.74M | 224.61M |
| Receivables | 939.87M | 808.56M | 645.66M | 796.91M |
| OtherReceivables | 25.60M | 15.52M | 17.80M | 41.74M |
| DuefromRelatedPartiesCurrent | 470.00K | 484.00K | 955.00K | 500.00K |
| TaxesReceivable | 18.66M | 16.83M | 13.17M | 12.88M |
| AccountsReceivable | 895.14M | 775.73M | 613.73M | 741.79M |
| AllowanceForDoubtfulAccountsReceivable | -845.18M | -528.06M | -586.25M | -603.17M |
| GrossAccountsReceivable | 1.74B | 1.30B | 1.20B | 1.34B |
| CashCashEquivalentsAndShortTermInvestments | 282.03M | 110.55M | 91.54M | 25.98M |
| CashAndCashEquivalents | 282.03M | 110.55M | 91.54M | 25.98M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 225.63M | 220.11M | 276.39M | -25.50M |
| RepaymentOfDebt | -2.81B | -233.12M | -414.08M | -123.27M |
| IssuanceOfDebt | 2.91B | 48.00M | 436.73M | 85.00M |
| CapitalExpenditure | -114.36M | -74.99M | -69.19M | -90.59M |
| InterestPaidSupplementalData | 197.85M | 263.52M | 192.81M | 142.72M |
| IncomeTaxPaidSupplementalData | 21.33M | 15.22M | 2.50M | 12.65M |
| EndCashPosition | 312.94M | 118.42M | 99.11M | 35.23M |
| BeginningCashPosition | 118.42M | 99.11M | 35.23M | 256.74M |
| EffectOfExchangeRateChanges | -1.68M | -999.00K | 65.00K | -5.68M |
| ChangesInCash | 196.20M | 20.31M | 63.81M | -215.83M |
| FinancingCashFlow | -31.53M | -211.79M | -212.57M | -106.62M |
| CashFlowFromContinuingFinancingActivities | -31.53M | -211.79M | -212.57M | -106.62M |
| NetOtherFinancingCharges | -134.73M | -27.83M | -235.68M | -69.01M |
| ProceedsFromStockOptionExercised | 1.96M | 1.15M | 451.00K | 662.00K |
| NetIssuancePaymentsOfDebt | 101.24M | -185.12M | 22.65M | -38.27M |
| NetShortTermDebtIssuance | -2.59B | -140.92M | -195.08M | 85.00M |
| ShortTermDebtPayments | -2.81B | -188.92M | -414.08M | |
| ShortTermDebtIssuance | 218.00M | 48.00M | 219.00M | 85.00M |
| NetLongTermDebtIssuance | 2.69B | -44.20M | 217.73M | -123.27M |
| LongTermDebtPayments | 0.00 | -44.20M | 0.00 | -123.27M |
| LongTermDebtIssuance | 2.69B | 0.00 | 217.73M | 0.00 |
| InvestingCashFlow | -112.26M | -63.00M | -69.19M | -174.31M |
| CashFlowFromContinuingInvestingActivities | -112.26M | -63.00M | -69.19M | -174.31M |
| NetOtherInvestingChanges | 1.00M | 5.00M | ||
| NetBusinessPurchaseAndSale | 0.00 | 11.99M | 0.00 | -84.71M |
| SaleOfBusiness | 0.00 | 11.99M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -84.71M | -146.54M |
| NetIntangiblesPurchaseAndSale | -15.51M | -14.65M | -22.39M | -41.80M |
| PurchaseOfIntangibles | -15.51M | -14.65M | -22.39M | -41.80M |
| NetPPEPurchaseAndSale | -96.75M | -60.34M | -46.80M | -48.80M |
| SaleOfPPE | 2.09M | 0.00 | 0.00 | |
| PurchaseOfPPE | -98.84M | -60.34M | -46.80M | -48.80M |
| OperatingCashFlow | 339.99M | 295.10M | 345.58M | 65.10M |
| CashFlowFromContinuingOperatingActivities | 339.99M | 295.10M | 345.58M | 65.10M |
| ChangeInWorkingCapital | -204.52M | -4.07M | -47.19M | -59.95M |
| ChangeInPayablesAndAccruedExpense | 22.25M | 289.58M | -84.62M | 111.64M |
| ChangeInPayable | 22.25M | 289.58M | -84.62M | 111.64M |
| ChangeInAccountPayable | 21.32M | 235.13M | -94.45M | 109.57M |
| ChangeInPrepaidAssets | -19.16M | -959.00K | 37.81M | 9.88M |
| ChangeInInventory | -87.03M | -130.53M | -126.18M | -102.40M |
| ChangeInReceivables | -120.58M | -162.16M | 125.80M | -79.07M |
| ChangesInAccountReceivables | -120.57M | -162.64M | 126.29M | -79.72M |
| OtherNonCashItems | 59.76M | 4.42M | 44.41M | 17.45M |
| StockBasedCompensation | 31.95M | 27.77M | 26.82M | 31.85M |
| ProvisionandWriteOffofAssets | 85.96M | 96.56M | 74.69M | 51.10M |
| AssetImpairmentCharge | 22.78M | 920.00K | 66.93M | 24.08M |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 223.57M | 236.19M | 229.40M | 240.18M |
| DepreciationAndAmortization | 223.57M | 236.19M | 229.40M | 240.18M |
| AmortizationCashFlow | 163.20M | 172.06M | 172.70M | |
| AmortizationOfIntangibles | 163.20M | 172.06M | 172.70M | |
| Depreciation | 66.20M | 68.11M | 60.70M | |
| OperatingGainsLosses | -7.45M | 7.19M | -768.00K | 15.19M |
| NetForeignCurrencyExchangeGainLoss | -7.45M | 7.19M | -768.00K | 15.19M |
| GainLossOnSaleOfPPE | 5.15M | |||
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | 127.93M | -73.88M | -48.72M | -254.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AMRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|